• Uma Rajeswari Batchu Institute of Pharmaceutical Technology Sri Padmavathi Mahila Viswavidyalayam Tirupati
  • Joshna Rani Surapaneni Professor Institute of Pharmaceutical Technology Sri Padmavathi Mahila Viswavidyalayam Tirupati


Nowadays the prevalence of hyperuricemia has significantly increased in which serum uric acid levels are exceeding the normal range. Gout is the predominant clinical implication of the hyperuricemia, but many clinical investigations have confirmed that hyperuricemia is an independent risk factor for cardiovascular disease (CVD), hypertension, diabetes, and many other diseases. The xanthine oxidase (XO) converts hypoxanthine to xanthine and ultimately to uric acid, and the irreversibly accumulated uric acid causes hyperuricemia associated with gout. Hence specific and selective xanthine oxidase inhibitors (XOI) are potentially powerful tools for inactivating target XO in the pathogenic process of hyperuricemia (Gout). The objective of the current study was to overview the various XOI isolated from the microorganisms. Microorganisms have been employed for several decades for the large-scale production of a variety of bio-chemicals ranging from alcohol to antibiotics and as well as enzyme inhibitors. Currently available XOI (allopurinol and febuxostat) for the treatment of gout have been exhibiting serious side effects. Thus, there is a need to search for new molecules to treat hyperuricemia and its associated disorders. At present, microbes have been unexplored in the development of successful products for the management of XO-related diseases. Hence, the present review focused on novel XOI produced from various microbial species such as Actinobacteria, lichens, bacteria, endophytic fungi and mushrooms, which can be expected to play an important role in the ongoing transition from the empirical screening to the real rational drug design.


Keywords: Xanthine oxidase inhibitors, Hyperuricemia, Actinobacteria, Bacteria, Fungi, Lichens


Download data is not yet available.

Author Biographies

Uma Rajeswari Batchu, Institute of Pharmaceutical Technology Sri Padmavathi Mahila Viswavidyalayam Tirupati
Joshna Rani Surapaneni, Professor Institute of Pharmaceutical Technology Sri Padmavathi Mahila Viswavidyalayam Tirupati


1. Feig DI. Uric acid. A novel mediator and marker of risk in chronic kidney disease. Curr Opin Nephrol Hypertens 2009;18:526-30.
2. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
3. Smith EU, Diaz-Torne C, Perez-Ruiz F, March LH. Epidemiology of gout. An update. Best Practice Res Clin Rheumatol 2010;24:811-27.
4. Pande I. An update on gout. Indian J Rheumatol 2006;1:60-5.
5. Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep 2005;7:235-41.
6. Ichida K, Amaya Y, Noda K, Minoshima S, Hosoya T, Sakai O, et al. Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): structural analysis of the protein and chromosomal location of the gene. Gene 1993;133:279-84.
7. Cazzaniga G, Terao M, Lo Schiavo P, Galbiati F, Segalla F, Seldin MF, et al. Chromosomal mapping, isolation, and characterization of the mouse xanthine dehydrogenase gene. Genomics 1994;23:390–402.
8. Minoshima S, Wang Y, Ichida K, Nishino T, Shimizu N. Mapping of the gene for human xanthine dehydrogenase (oxidase) (XDH) to band p23 of chromosome 2. Cytogen Cell Gen 1995;68 (1, Suppl 2):52-3.
9. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vas Health Risk Manag 2009;5:265-72.
10. Reuter S, Gupta SC, Chaturvedi MM, Aggarwa BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med 2010;49:1603-16.
11. Sachidanandam C, Fagan SC, Ergul A. Oxidative stress and cardiovascular disease: antioxidants and unresolved issues. Cardiovasc Drug Rev 2005;23:115-32.
12. Uma Rajeswari B, Kiranmai M. Biochemical role of xanthin oxidoreductase and its natural inhibitors. Int J Pharm Pharm Sci 2016;8:57-65.
13. Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther 2011;336:95–103.
14. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity, description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
15. Abeles AM. Febuxostat hypersensitivity. J Rheumatol 2012;39:659.
16. Changyi Chen, Jian Ming Lu, Qizhi Yao. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Med Sci Mon 2016;22:2501-12.
17. Pandey M, Debnath M, Gupta S, Chikara SK. Phytomedicine: an ancient approach is turning in to future potential source of therapeutics. J Pharmacognosy Phytother 2011;3:27-37.
18. Umezawa H. Enzyme inhibitors of microbial origin. Univ Tokyo Press; 1972. p. 109.
19. Ajay Kumar, Wamik Azmi. Phytomedicine: a novel alternative for treatment of gout. Ann Phytomed 2014;3:80-8.
20. Bhupinder Kapoor, Gagandeep Kaur, Mukta Gupta, Reena Gupta. Indian medicinal plants useful in treatment of gout: a review for current status and future perspective. Asian J Pharm Clin Res 2017;10:407-16.
21. Rohit R Patil, Gajanan S Patil. A review: antigout medicinal plants. Eur J Biomed Pharm Sci 2018;5:394-402.
22. Ling X, Bochu W. A review of phytotherapy of gout: perspective of new pharmacological treatments. Pharmazie 2014;69:243–56.
23. Ojha R, Singh J, Ojha A, Singh H, Sharma S, Nepali K. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat 2017;27:311-45.
24. Schindler P, Hartley BS, Brenner S. Enzyme inhibitors of microbial origin. Phil Trans Royal Soc London B 1980;290:291-301.
25. Pandey A, Selvakumar P, Soccol CR, Nigam P. Solid-state fermentation for the production of industrial enzymes. Curr Sci 1999;77:149–62.
26. Panda H. Handbook on drugs from natural sources. Asia Pacific Business Press Inc; 2000. p. 1-34.
27. Suahara N, Nogi K, Yokogava K. Production of xanthine oxidase inhibitor, 2,8-Dihydroxy adenine by Alcaligenes aquamarinus. Agric Bioll Chem 1977;41:1103-9.
28. Cavalieri LF, Bendich A. The ultraviolet absorption spectra of pyrimidines and purines. J Am Chem Soc 1950;72:2587-94.
29. Izumida H, Adachi K, Nishijima M, Endo M, Miki W. Akalone: a novel xanthine oxidase inhibitor produced by the marine bacterium, Agrobacterium aurantiacum sp. nov. J Marine Biotechnol 1995;2:115-8.
30. Izumida H, Adachi K, Mihara A, Yasuzawaft T, Sano H. Hydroxyakalone, a novel xanthine oxidase inhibitor produced by a marine bacterium, Agrobacterium aurantiacum. J Antibiotics 1997;50:916-8.
31. Siao Jen Chen, Yen-Lin Chen, Hsun Yin Hsu, Shy Yunn Wann. Novel strains of lctobacillus rhamnosus and its metabolites for use in inhibing xanthine oxidase and treating gout. US2016/0051602AD; 2016.
32. Siao Jen Chen, Yen Lin Chen, Hsun Yin Hsu, Shy Yunn Wann. Novel acetobacter and gluconobacter strains and their metabolites for use in inhibiting xanthine oxidase. US2016/0051596A1; 2018.
33. Siao Jen Chen, Yen Lin Chen, Hsun Yin Hsu, Shy Yunn Wann. Acetobacter and Gluconobacter strains and their metabolites for use in inhibiting Xanthine oxidase. US9,86,7857 B2; 2018.
34. Yamamoto Y, Miura Y, Higuchi M, Kinoshita Y, Yoshimura I. Using lichen tissue culture in modern biology. Bryologist 1993;96:384–93.
35. Yamamoto Y, Kinoshita Y, Matsubara H, Kinoshita K, Koyama K, Takahashi K, et al. Screening of biological activities and isolation of biological-active compounds from lichens. Res J Phytochem 1998;2:23–34.
36. Behera BC, Adawadkar B, Makhij U. Tissue culture of Bulbothrix setschwanensis (lichenized ascomycetes) in vitro. Curr Sci 2000;78:781–3.
37. Behera BC, Urmila Makhija. Inhibition of tyrosinase and xanthine oxidase by lichen species Bulbothrix setschwanensis. Curr Sci 2002;82:61-6.
38. Behera BC, Adawadkar B, Makhij U. Capacity of some graphidaceous lichens to scavenge superoxide and inhibition of tyrosinase and xanthine oxidase activities. Curr Sci 2004;87:83-7.
39. Nisa H, Kamiti AN, Nawchoo IA, Shafi S, Shameen N, Bandh SA. Fungal endophytes as a prolific source of phytochemicals and other bioactive natural products: a review. Microboil Pathol 2015;82:50-9.
40. Tan RX, Zou WX. Endophytes: a rich source of functional metabolites. Nat Prod Rep 2001;18:458-9.
41. Zhang HW, Song YC, Tan RX. Biology and chemistry of endophytes. Nat Prod Rep 2006;23:828-9.
42. Song YC, Li H, Ye YH, Shan CY, Yang YM, Tan RX. Endophytic naphthopyrone metabolites are co-inhibitors of xanthine oxidase, SW1116 cell and some microbial growths. FEMS Microb Lett 2004;241:67–72.
43. Shu RG, Wang FW, Yang YM, Liu YX, Tan RX. Antibacterial and xanthine oxidase inhibitory cerebrosides from Fusarium sp. IFB-121, and endophytic fungus in quercus variabilis. Lipids 2004;39:667–73.
44. Huang WY, Cai YZ, Hyde KD, Corke H, Sun M. Endophytic fungi from Nerium oleander L (Apocynaceae): main constituents and antioxidant activity. World J Microb Biotechnol 2007;23:1253–63.
45. Kapoor N, Saxena S. Xanthine oxidase inhibitory and antioxidant potential of Indian Muscodor species. 3 Biotech 2016;6:248.
46. Neha Kapoor, Sanjai Saxena. Endophytic fungi of Tinospora cordifolia with anti-gout properties. Biotechnology 2018;8:264-70.
47. Kapoor N, Saxena S. Potential xanthine oxidase inhibitory activity of endophytic Lasiodiplodia pseudotheobromae. Appl Biochem Biotechnol 2014;173:1360–74.
48. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Biochem Biotechnol 2002;60:258-74.
49. Mahajna J, Dotan N, Zaidman BZ, Petrova RD, Wasser SP. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutr Cancer 2009;61:16-26.
50. Rastelli G, Costantino L, Albasini A. Theoretical and experimental study of flavones as inhibitors of Xanthine oxidase. Eur J Med Chem 1995;30:141-6.
51. Vanishree B, Dayanand CD, Sheela SR. Evaluation of xanthine oxidase inhibitory activity by flavonoids from pongamia pinnata Linn. Asian J Pharm Clin Res 2017;10:360-2.
52. Chang WS, Lee YJ, Lu FJ, Chaing HC. Inhibitory effects of flavonoids on xanthine oxidase. Anticancer Res 1993;13:2163-70.
53. Lio M, Moriyama A, Matsumoto Y, Takaki N, Fukumoto M. Inhibition of xanthine oxidase by flavonoids. Agric Biol Chem 1985;49:2173-6.
54. Hilaire V, Kemami Wangun. Inotilone and related phenyl-propanoid polyketides from Inonotus sp. and their identification as potent COX and XO inhibitors. Org Biomol Chem 2006;4:2545–8.
55. Alam N, Yoon KN, Jeong C. Appraisal of the antioxidant, phenolic compounds, concentration, xanthine oxidase, tyrosine oxidase inhibitory activities of Pleurotus salmoneoshamineus. Afr JAgric Res 2011;6:1555-63.
56. Alam N, Yoon KN, Tae Soo Lee. Evaluation of the antioxidant and antityrosinase activities of three extracts from Pleurotus nebrodensis. Afr J Biotechnol 2011;10:2978-86.
57. Jang IT, Hyun SH, Lee YH. Characterization of an anti-gout xanthine oxidase inhibitor from pleurotus ostreatus. Mycobiology 2014;42:296-300.
58. Kovacs B, Zomborszki ZP, Gyapai OO, Loffler JC, Busa EL, Lazar A, et al. Investigation of antimicrobial, antioxidant, and xanthine oxidase−inhibitory activities of Phellinus (Agaricomycetes) mushroom species native to central Europe. Int J Med Mushrooms 2018;20:387-94.
59. Yang HS, Choi YJ, Oh HH, Moon JS. Antioxidant activity of mushroom water extracts fermented by Lactic acid bacteria. J Korean Soc Food Sci Nutr 2014;43:80-5.
60. Attila Ványolós, Orsolya Orbán-Gyapai and Judit Hohmann. Xanthine Oxidase Inhibitory Activity of Hungarian Wild-Growing Mushrooms. Phytother Res 2014.
509 Views | 631 Downloads
How to Cite
Batchu, U., and J. Surapaneni. “EXPLORATION OF MICROORGANISMS AS A POTENTIAL SOURCE OF XANTHINE OXIDASE INHIBITORS: AN UPDATED REVIEW”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 10, no. 12, Dec. 2018, pp. 1-4, doi:10.22159/ijpps.2018v10i12.29897.
Review Article(s)